CA2388777A1 - 18 proteines secretees humaines - Google Patents

18 proteines secretees humaines Download PDF

Info

Publication number
CA2388777A1
CA2388777A1 CA002388777A CA2388777A CA2388777A1 CA 2388777 A1 CA2388777 A1 CA 2388777A1 CA 002388777 A CA002388777 A CA 002388777A CA 2388777 A CA2388777 A CA 2388777A CA 2388777 A1 CA2388777 A1 CA 2388777A1
Authority
CA
Canada
Prior art keywords
seq
polypeptide
human
polypeptides
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002388777A
Other languages
English (en)
Inventor
Steven M. Ruben
George A. Komatsoulis
Kevin P. Baker
Paul E. Young
Gil H. Choi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2388777A1 publication Critical patent/CA2388777A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne de nouvelles protéines sécrétées humaines et des acides nucléiques isolés contenant les régions codantes des gènes codant pour ces protéines. L'invention concerne également des vecteurs, des cellules hôtes, des anticorps et des procédés de recombinaison permettant de produire les protéines sécrétées humaines. L'invention concerne en outre des méthodes diagnostiques et thérapeutiques utiles pour diagnostiquer et traiter des maladies, des troubles et/ou des conditions liés à ces nouvelles protéines sécrétées humaines.
CA002388777A 1999-11-19 2000-11-15 18 proteines secretees humaines Abandoned CA2388777A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US16641599P 1999-11-19 1999-11-19
US60/166,415 1999-11-19
US21513600P 2000-06-30 2000-06-30
US60/215,136 2000-06-30
PCT/US2000/031162 WO2001036432A2 (fr) 1999-11-19 2000-11-15 18 proteines secretees humaines

Publications (1)

Publication Number Publication Date
CA2388777A1 true CA2388777A1 (fr) 2001-05-25

Family

ID=26862246

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002388777A Abandoned CA2388777A1 (fr) 1999-11-19 2000-11-15 18 proteines secretees humaines

Country Status (5)

Country Link
EP (1) EP1234030A4 (fr)
JP (1) JP2003514541A (fr)
AU (1) AU1604401A (fr)
CA (1) CA2388777A1 (fr)
WO (1) WO2001036432A2 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8007798B2 (en) 1997-11-21 2011-08-30 Genentech, Inc. Treatment of complement-associated disorders
US7419663B2 (en) 1998-03-20 2008-09-02 Genentech, Inc. Treatment of complement-associated disorders
US7192589B2 (en) * 1998-09-16 2007-03-20 Genentech, Inc. Treatment of inflammatory disorders with STIgMA immunoadhesins
US8088386B2 (en) 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
WO2002016429A2 (fr) * 2000-08-24 2002-02-28 Genentech, Inc. Compositions et procedes de diagnostic et traitement de tumeurs
AU7684201A (en) 2000-06-28 2002-01-08 Glycofi Inc Methods for producing modified glycoproteins
US7625756B2 (en) 2000-06-28 2009-12-01 GycoFi, Inc. Expression of class 2 mannosidase and class III mannosidase in lower eukaryotic cells
US7449308B2 (en) 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
US7598055B2 (en) 2000-06-28 2009-10-06 Glycofi, Inc. N-acetylglucosaminyltransferase III expression in lower eukaryotes
US20040152105A1 (en) * 2002-09-06 2004-08-05 Cytos Biotechnology Ag. Immune modulatory compounds and methods
US7332299B2 (en) * 2003-02-20 2008-02-19 Glycofi, Inc. Endomannosidases in the modification of glycoproteins in eukaryotes
JP4897690B2 (ja) * 2004-10-12 2012-03-14 ジェネンテック， インコーポレイテッド 補体関連障害の予防および処置のためのＣＲＩｇポリペプチド
KR20170002684A (ko) 2005-11-04 2017-01-06 제넨테크, 인크. 안질환 치료를 위한 보체 경로 억제제의 용도
US7776573B2 (en) 2006-06-01 2010-08-17 Genentech, Inc. Crystal structure of CRIg and C3b:CRIg complex
PE20121034A1 (es) 2006-11-02 2012-08-25 Genentech Inc Anticuerpos anti-factor d humanizados
AR066660A1 (es) 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
KR101690590B1 (ko) 2008-05-06 2016-12-28 제넨테크, 인크. 친화력-성숙 ＣＲＩｇ 변이체
KR101137019B1 (ko) 2009-05-25 2012-05-24 한국생명공학연구원 신규한 ｇｐｃｒ 단백질 및 이의 용도
US20130101590A1 (en) 2010-04-09 2013-04-25 Heather A. Arnett Btnl9 proteins, nucleic acids, and antibodies and uses thereof
CN107318267B (zh) 2013-08-12 2021-08-17 豪夫迈·罗氏有限公司 用于治疗补体相关的病症的组合物和方法
EA201692109A1 (ru) 2014-05-01 2017-03-31 Дженентек, Инк. Варианты антител к фактору d и их применение
CN108289951A (zh) 2015-10-30 2018-07-17 豪夫迈·罗氏有限公司 抗-因子d抗体和缀合物
EP3368090A1 (fr) 2015-10-30 2018-09-05 H. Hoffnabb-La Roche Ag Conjugués de variants d'anticorps anti-facteur d et leurs utilisations
WO2017150681A1 (fr) * 2016-03-03 2017-09-08 東亞合成株式会社 Procédé de diagnostic de sclérose latérale amyotrophique utilisant un peptide signal comme index

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999001550A1 (fr) * 1997-07-03 1999-01-14 Dana-Farber Cancer Institute Procede de detection de modifications de msh5
JPH11313673A (ja) * 1998-04-30 1999-11-16 Hoechst Marion Roussel Kk ヒトｂｍｐ−２プロモーターおよびこれを用いた骨関連物質の探索法
EP1224281A4 (fr) * 1999-09-27 2003-10-15 Human Genome Sciences Inc 37 proteines secretees humaines

Also Published As

Publication number Publication date
EP1234030A4 (fr) 2003-05-07
AU1604401A (en) 2001-05-30
WO2001036432A3 (fr) 2002-05-10
WO2001036432A2 (fr) 2001-05-25
JP2003514541A (ja) 2003-04-22
EP1234030A2 (fr) 2002-08-28

Similar Documents

Publication Publication Date Title
CA2388777A1 (fr) 18 proteines secretees humaines
CA2387959A1 (fr) 21 proteines humaines secretees
CA2383800A1 (fr) 52 proteines humaines secretees
CA2388822A1 (fr) 27 proteines humaines secretees
CA2387799A1 (fr) 19 proteines humaines secretees
CA2385475A1 (fr) 18 proteines secretees humaines
CA2382185A1 (fr) 48 proteines secretees humaines
CA2383041A1 (fr) 49 proteines secretees humaines
CA2370489A1 (fr) 49 proteines humaines secretees
CA2388922A1 (fr) 23 proteines humaines secretees
CA2386641A1 (fr) 32 proteines humaines secretees
CA2370767A1 (fr) 49 proteines humaines secretees
CA2382148A1 (fr) 25 proteines secretees humaines
CA2368281A1 (fr) 50 proteines humaines secretees
CA2365522A1 (fr) 48 proteines secretees humaines
CA2368302A1 (fr) 49 proteines secretees par un etre humain
CA2364635A1 (fr) 47 proteines humaines secretees
CA2403901A1 (fr) 29 proteines humaines secretees
CA2385169A1 (fr) 43 proteines secretees humaines
CA2388914A1 (fr) 15 proteines humaines secretees
CA2389724A1 (fr) 28 proteines humaines secretees
CA2387261A1 (fr) 25 proteines secretes par l'homme
CA2387964A1 (fr) 22 proteines humaines secretees
CA2388019A1 (fr) 24 proteines humaines secretees
CA2371172A1 (fr) 50 proteines humaines secretees

Legal Events

Date Code Title Description
FZDE Dead